This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00957268
First received: August 6, 2009
Last updated: January 26, 2015
Last verified: January 2015
History of Changes
Results First Received: November 21, 2014  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Alogliptin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants took part in the study at 6 investigative sites in the United States from 17 Sep 2009 to 22 Nov 2013.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants aged 10 to 65 with a diagnosis of type 2 diabetes mellitus were enrolled in 1 of 5 treatment groups and received 12.5 or 25 mg alogliptin once.

Reporting Groups
  Description
Alogliptin 12.5 mg (Age 10 to < 14 Years) Alogliptin 12.5 mg QD, tablets, orally, 1 dose only.
Alogliptin 25 mg (Age 10 to < 14 Years) Alogliptin 25 mg QD, tablets, orally, 1 dose only.
Alogliptin 12.5 mg (Age 14 to < 18 Years) Alogliptin 12.5 mg QD, tablets, orally, 1 dose only.
Alogliptin 25 mg (Age 14 to < 18 Years) Alogliptin 25 mg QD, tablets, orally, 1 dose only.
Alogliptin 25 mg (Age 18 to 65 Years) Alogliptin 25 mg QD, tablets, orally, 1 dose only.

Participant Flow:   Overall Study
    Alogliptin 12.5 mg (Age 10 to < 14 Years)   Alogliptin 25 mg (Age 10 to < 14 Years)   Alogliptin 12.5 mg (Age 14 to < 18 Years)   Alogliptin 25 mg (Age 14 to < 18 Years)   Alogliptin 25 mg (Age 18 to 65 Years)
STARTED   5   4   8   7   22 
COMPLETED   5   4   7   7   22 
NOT COMPLETED   0   0   1   0   0 
Voluntary Withdrawal                0                0                1                0                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Safety set: All enrolled participants who received at least 1 dose of study drug.

Reporting Groups
  Description
Alogliptin 12.5 mg (Age 10 to < 14 Years) Alogliptin 12.5 mg QD, tablets, orally, 1 dose only.
Alogliptin 25 mg (Age 10 to < 14 Years) Alogliptin 25 mg QD, tablets, orally, 1 dose only.
Alogliptin 12.5 mg (Age 14 to < 18 Years) Alogliptin 12.5 mg QD, tablets, orally, 1 dose only.
Alogliptin 25 mg (Age 14 to < 18 Years) Alogliptin 25 mg QD, tablets, orally, 1 dose only.
Alogliptin 25 mg (Age 18 to 65 Years) Alogliptin 25 mg QD, tablets, orally, 1 dose only.
Total Total of all reporting groups

Baseline Measures
   Alogliptin 12.5 mg (Age 10 to < 14 Years)   Alogliptin 25 mg (Age 10 to < 14 Years)   Alogliptin 12.5 mg (Age 14 to < 18 Years)   Alogliptin 25 mg (Age 14 to < 18 Years)   Alogliptin 25 mg (Age 18 to 65 Years)   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 5   4   8   7   22   46 
Age 
[Units: Years]
Mean (Standard Deviation) 		 12.4  (0.89)   12.0  (0.82)   15.4  (0.92)   15.1  (0.69)   51.3  (8.24)   31.96  (19.67) 
Gender 
[Units: Participants]
 		           
Female   4   3   6   5   16   34 
Male   1   1   2   2   6   12 
Race/Ethnicity, Customized 
[Units: Participants]
 		           
Hispanic or Latino   0   1   1   1   4   7 
Non-Hispanic or Latino   5   3   7   6   18   39 
Race/Ethnicity, Customized 
[Units: Participants]
 		           
Asian Black or African American   5   3   4   5   15   32 
White   0   1   4   2   7   14 
Height 
[Units: Cm]
Mean (Standard Deviation) 		 162.4  (8.56)   165.8  (8.88)   168.6  (5.71)   168.9  (9.03)   167.5  (9.81)   167.2  (8.73) 
Weight 
[Units: Kg]
Mean (Standard Deviation) 		 86.62  (13.979)   98.90  (11.957)   116.28  (33.163)   103.71  (17.103)   92.25  (16.454)   97.14  (21.409) 
Body Mass Index (BMI) 
[Units: Kg/m^2]
Mean (Standard Deviation) 		 33.22  (4.621)   36.16  (3.422)   40.92  (9.190)   36.46  (6.764)   32.84  (4.490)   35.01  (6.439) 
Smoking Status 
[Units: Participants]
 		           
Never Smoked   5   4   8   7   14   38 
Current Smoker   0   0   0   0   0   0 
Ex-smoker   0   0   0   0   8   8 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Cmax: Maximum Observed Plasma Concentration for Alogliptin   [ Time Frame: 1 hour pre-dose and 1, 2, 4, 8, 12, 16, 24, 48, and 72 hours post-dose ]
  Show Outcome Measure 1

2.  Primary:   Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alogliptin   [ Time Frame: 1 hour pre-dose and 1, 2, 4, 8, 12, 16, 24, 48, and 72 hours post-dose ]
  Show Outcome Measure 2

3.  Primary:   AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alogliptin   [ Time Frame: 1 hour pre-dose and 1, 2, 4, 8, 12, 16, 24, 48, and 72 hours post-dose ]
  Show Outcome Measure 3

4.  Secondary:   Area Under the Plasma Effect-Time Curve From Time 0 to 24 Hours Post-dose (AUEC[0-24]) of Dipeptidyl Peptidase-4 (DPP-4) Inhibition   [ Time Frame: 1 hour pre-dose and 2, 4, 8, 12, and 24 hours post-dose ]
  Show Outcome Measure 4

5.  Secondary:   Maximum Observed Effect (Emax) of Dipeptidyl Peptidase-4 (DPP-4) Inhibition   [ Time Frame: 1 hour pre-dose and 2, 4, 8, 12, and 24 hours post-dose ]
  Show Outcome Measure 5

6.  Secondary:   Time to Reach the Maximum Observed Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition   [ Time Frame: 1 hour pre-dose and 2, 4, 8, 12, and 24 hours post-dose ]
  Show Outcome Measure 6

7.  Secondary:   Observed Effect at 24 Hours Post-dose (E24) of Dipeptidyl Peptidase-4 (DPP-4) Inhibition   [ Time Frame: 1 hour pre-dose and 2, 4, 8, 12, and 24 hours post-dose ]
  Show Outcome Measure 7

8.  Secondary:   Area Under the Plasma Effect-Time Curve From Time 0 to 24 Hours Post-dose (AUEC[0-24]) of the Baseline-corrected Glucagon-like Peptide-1 (GLP-1) Concentration   [ Time Frame: 1 hour pre-dose and 2, 4, 8, 12, and 24 hours post-dose ]
  Show Outcome Measure 8

9.  Secondary:   Maximum Observed Effect (Emax) of the Baseline-corrected Glucagon-like Peptide-1 (GLP-1) Concentration   [ Time Frame: 1 hour pre-dose and 2, 4, 8, 12, and 24 hours post-dose ]
  Show Outcome Measure 9

10.  Secondary:   Time to Reach the Maximum Observed Effect of the Baseline-corrected Glucagon-like Peptide-1 (GLP-1) Concentration   [ Time Frame: 1 hour pre-dose and 2, 4, 8, 12, and 24 hours post-dose ]
  Show Outcome Measure 10

11.  Secondary:   Observed Effect at 24 Hours Post-dose (E24) of the Baseline-corrected Glucagon-like Peptide-1 (GLP-1) Concentration   [ Time Frame: 1 hour pre-dose and 2, 4, 8, 12, and 24 hours post-dose ]
  Show Outcome Measure 11


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Director, Clinical Science
Organization: Takeda
phone: 800-778-2860
e-mail: clinicaltrialregistry@tpna.com



Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00957268     History of Changes
Other Study ID Numbers: SYR-322_104
2009-011221-13 ( Registry Identifier: EudraCT )
U1111-1111-7810 ( Registry Identifier: WHO )
Study First Received: August 6, 2009
Results First Received: November 21, 2014
Last Updated: January 26, 2015